Subsequent guidelines and expert consensus have recognised the importance of atherogenic dyslipidaemia as a key driver of CV risk in insulin-resistant states, even if LDL cholesterol levels are well controlled [8-12]. The gene discussed is INS; the disease is inherited lipid metabolism disorder.